The biopharmaceutical contract manufacturing market is estimated to be worth USD 13.9 billion in 2030, predicts Roots Analysis
Roots Analysis is pleased to announce the publication of its recent study, titled, “Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030.”
115
views

Outsourcing hasbecome a popular trend among biopharmaceutical developers, allowing them toleverage the expertise / larger production capacities of CMOs / CDMOs andachieve significant cost and time related advantages

 

Roots Analysis is pleased toannounce the publication of its recent study, titled,  “Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030.” 

 

The report features an extensivestudy on the contract service providers within the biopharmaceutical industry.The study features in-depth analysis, highlighting the capabilities of adiverse set of biopharmaceutical CMOs and CDMOs. Amongst other elements, thereport includes:

§ A detailed review of theoverall landscape of the biopharmaceutical contract manufacturing market,featuring a comprehensive list of active CMOs and detailed analysis of themanufacturing service providers based on a number of parameters.

§ Elaborate profiles ofkey players that have a diverse range of capabilities for the development,manufacturing, and packaging of biologics.

§  A detailed discussion on the key enablers in this domain,including certain niche product classes, which are likely to have a significant impact on the growthof the contract services market.

§  A case study on the growing global biosimilars market,highlighting the opportunities for biopharmaceutical CMOs and CDMOs.

§  A case study comparing the key characteristics of largemolecule and small molecule drugs, along with details on the various stepsinvolved in their respective manufacturing processes.

§  A discussion on challenges related to in-housemanufacturing, featuring a brief overview of the various parameters that a drug/ therapy developer may need to take into consideration while deciding whetherto manufacture its products in-house or outsource.

§ An analysis of therecent collaborations (signed since 2013) focused on the contract manufacturingof biologics.

§ A detailed analysisof the various mergers and acquisitions that have taken place in this domain,highlighting the trend in the number of companies acquired between 2013-2018,along with the geographical distribution of this activity.

§ An in-depth analysisof more than 490 grants that have been awarded to research institutes engagedin next generation immune checkpoint therapy-related projects.

§ An analysis on therecent trends within biopharmaceutical contract manufacturing industry,highlighting various facility and capability expansions.

§ A detailed capacityanalysis, taking into consideration the individual development andmanufacturing capacities of various stakeholders.

§ A detailed capacityanalysis, taking into consideration the individual development andmanufacturing capacities of various stakeholders.

§ A discussion onaffiliated trends, key drivers, and challenges, under a comprehensive SWOTframework.

§  A survey analysis featuring inputs solicited from variousexperts who are directly / indirectly involved in providing CMO services tomedical device developers.

§  A detailed marketforecast, featuring analysis of the current and projected future opportunityacross key market segments (listed below)

§ Commonly OutsourcedBusiness Operations

§ Active PharmaceuticalIngredients (API)

§ Finished Dosage Formulations(FDF)

§ Types of ExpressionSystem

§ Mammalian

§ Microbial

§ Others

§ Company Size

§ Small

§ Mid-Sized

§ Large and Very Large

§ Scale of Operation

§ Preclinical

§ Clinical

§ Commercial

§ Key GeographicalRegion 

§ North America

§ Europe

§ Asia-Pacific

§ Rest of theWorld 

 

The report also features detailed transcripts ofdiscussions held with the following experts:

§  Astrid Brammer, Senior Manager Business Development,Richter-Helm Mathias Schmidt (Chief Executive Officer, ArmaGen)

§  Birgit Schwab, Senior Manager Strategic Marketing,Rentschler Biotechnologie

§  Christian Bailly, Director of CDMO, Pierre Fabre

§  Claire Otjes, Assistant Marketing Manager, BataviaBiosciences

§  David C Cunningham, Director Corporate Development, GoodwinBiotechnology

§  Dietmar Katinger, Chief Executive Officer, PolymunScientific

§  Denis Angioletti, Chief Commercial Officer, Cerbios-Pharma

§  Jeffrey Hung, Chief Commercial Officer, Vigene Biosciences

§  Kevin Daley, Director Pharmaceuticals, Novasep

§  Mark Wright, Site Head, Grangemouth, Piramal Healthcare

§  Nicolas Grandchamp, R&D Leader, GEG Tech

§  Raquel Fortunato, Chief Executive Officer, GenIbetBiopharmaceuticals

§  Sebastian Schuck, Head of Business Development, WackerBiotech

§  Stephen Taylor, Senior Vice President Commercial, FUJIFILMDiosynth Biotechnologies

§  Tatjana Buchholz, Marketing Manager, PlasmidFactory andMarco Schmeer, Project Manager, PlasmidFactory

§  Tim Oldham, Chief Executive Officer, Cell Therapies

 

Keycompanies covered in the report

§  3P Biopharmaceuticals

§  Abzena

§  Albany Molecular Research

§  BioVectra

§  BioXcellence (Boehringer Ingelheim)

§  Celonic

§  Charles River Laboratories

§  ChemPartner

§  Cobra Biologics

§  CordenPharma

§  Cytovance Biologics

§  GE Healthcare

§  Goodwin Biotechnology

§  Grand River Aseptic Manufacturing

§  IDT Biologika

§  KBI BioPharma

§  Kemwell Biopharma

§  LFB Biomanufacturing

§  Meridian Life Science

§  Patheon

§  Pfizer CentreOne

§  PX'Therapeutics

§  Samsung BioLogics

§  Sanofi, CEPiA

§  Thermo Fisher Scientific

§  Vetter Pharma International

 

Formore information please click on the following link:

BiopharmaContract Manufacturing Market (3rd Edition), 2019-2030

 

Other Recent Offerings

1.     CellTherapy Manufacturing Market (3rdEdition), 2019-2030

2.     AntibodyContract Manufacturing Market, 2020-2030

3.     China Biopharmaceutical ContractManufacturing Market,2020-2030

4.     PeptideTherapeutics: Contract API ManufacturingMarket, 2020-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growingmarket research companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com